Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Vickerman

Showing results (31-40 of 397) with videos related to

Pageof 40
Sort By:
The Lancet. Gastroenterology & Hepatology|November 28, 2018
Hepatitis case finding among migrants in primary careMatthew Hickman, Sema Mandel, Peter Vickerman, et al.
Addiction (Abingdon, England)|February 7, 2020
Prisons can also improve drug user health in the communityNatasha K Martin, Matthew Hickman, Anne C Spaulding, et al.
BMJ (Clinical Research Ed.)|July 24, 2004
Condoms and prevention of HIVAnna M Foss, Charlotte H Watts, Peter Vickerman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 2, 2025
Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central AsiaJosephine G Walker, Irina Tskhomelidze Schumacher, Adam Trickey, et al.
BMC Infectious Diseases|September 20, 2008
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in EnglandVivian Hope, Jo Kimber, Peter Vickerman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C VirusChristopher G Fawsitt, Peter Vickerman, Graham Cooke, et al.
Addiction (Abingdon, England)|November 20, 2009
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysisPeter Vickerman, Matthew Hickman, Margaret May, et al.
Journal of Public Health (Oxford, England)|July 27, 2011
Promoting recovery and preventing drug-related mortality: competing risks?Matt Hickman, Peter Vickerman, Roy Robertson, et al.
Current Opinion in HIV and AIDS|August 7, 2015
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Addiction (Abingdon, England)|March 17, 2007
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and WalesMatthew Hickman, Peter Vickerman, John Macleod, et al.
Pageof 40

Showing results (31-40 of 397) with videos related to

Sort By:
Pageof 40
The Lancet. Gastroenterology & Hepatology|November 28, 2018
Hepatitis case finding among migrants in primary careMatthew Hickman, Sema Mandel, Peter Vickerman, et al.
Addiction (Abingdon, England)|February 7, 2020
Prisons can also improve drug user health in the communityNatasha K Martin, Matthew Hickman, Anne C Spaulding, et al.
BMJ (Clinical Research Ed.)|July 24, 2004
Condoms and prevention of HIVAnna M Foss, Charlotte H Watts, Peter Vickerman, et al.
Liver International : Official Journal of the International Association for the Study of the Liver|July 2, 2025
Cost-Effectiveness of Hepatitis C Virus Case Finding and Treatment in Eastern Europe and Central AsiaJosephine G Walker, Irina Tskhomelidze Schumacher, Adam Trickey, et al.
BMC Infectious Diseases|September 20, 2008
Frequency, factors and costs associated with injection site infections: findings from a national multi-site survey of injecting drug users in EnglandVivian Hope, Jo Kimber, Peter Vickerman, et al.
Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research|June 15, 2019
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C VirusChristopher G Fawsitt, Peter Vickerman, Graham Cooke, et al.
Addiction (Abingdon, England)|November 20, 2009
Can hepatitis C virus prevalence be used as a measure of injection-related human immunodeficiency virus risk in populations of injecting drug users? An ecological analysisPeter Vickerman, Matthew Hickman, Margaret May, et al.
Journal of Public Health (Oxford, England)|July 27, 2011
Promoting recovery and preventing drug-related mortality: competing risks?Matt Hickman, Peter Vickerman, Roy Robertson, et al.
Current Opinion in HIV and AIDS|August 7, 2015
The hepatitis C virus epidemics in key populations (including people who inject drugs, prisoners and MSM): the use of direct-acting antivirals as treatment for preventionNatasha K Martin, Peter Vickerman, Gregory J Dore, et al.
Addiction (Abingdon, England)|March 17, 2007
Cannabis and schizophrenia: model projections of the impact of the rise in cannabis use on historical and future trends in schizophrenia in England and WalesMatthew Hickman, Peter Vickerman, John Macleod, et al.
Pageof 40